US equities |
TSLA $357.91 ▼-1.25% MU $897.36 ▼-3.64% NVDA $217.47 ▲+0.11% AAPL $345.30 ▲+0.96% SPCX $146.55 ▼-1.39% META $720.31 ▼-2.23% SNDK $1,333.86 ▼-4.37% AMD $542.25 ▼-3.55%
FinancialContent

Articles published by Pharvaris N.V.

< Previous 1 2 3 Next >
News headline image
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Announces Extraordinary Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris to Present at the WSAAI Annual Meeting 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris to Present at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris To Present at the APAAACI 2023 International Conference
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris To Present at the CIIC Fall 2023 Conference
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris To Present at the 18th German Allergy Congress
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Announces $70 Million Private Placement Financing
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
News headline image
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
From Pharvaris N.V.
Via GlobeNewswire
Tickers PHVS
< Previous 1 2 3 Next >